Liraglutide and Dpp-4 inhibitors – side effects comparative clinical study
Keywords:
liraglutide, DPP-4 inhibitors, side effectsAbstract
The objective of this study was to monitor the side effects of the GLP-1 receptoragonist liraglutide in comparison to those of DPP-4 inhibitors (sitagliptin and
vildagliptin), in order to determine their safety, tolerability and therapeutic efficiency.
The study was carried out in the “Heart and Diabetes Center NRW“ and included
overweight patients with type 2 diabetes whose therapeutic regimen was switched to
liraglutide or DPP-4 inhibitors. A validated questionnaire method was used to monitor
the side effects during the hospitalization period, then again at 3, and 6 months after the
beginning of the therapy.
The therapy with liraglutide was associated with more side effects than the one
with DPP-4 inhibitors. In general, side effects were declining with time, thus only few
patients stopped therapy. The incretin therapy turned out to be a safe and effective
therapeutic option for patients with type 2 diabetes mellitus.
Downloads
Published
2013-11-12
How to Cite
1.
Timofte L, Stratmann B, Quester W, Bojiță MT, Tschoepe D. Liraglutide and Dpp-4 inhibitors – side effects comparative clinical study. Med Pharm Rep [Internet]. 2013 Nov. 12 [cited 2025 Oct. 6];86(2):111-3. Available from: https://medpharmareports.com/index.php/mpr/article/view/5
Issue
Section
Original Research
License
The authors are required to transfer the copyright of the published paper to the journal. This is done by agreeing to sign the Copyright Assignment Form. Whenever the case, authors are also required to send permissions to reproduce material (such as illustrations) from the copyright holder.
The papers published in the journal are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.